Emcure Pharma Share Price in Focus; Signs Roche Distribution Deal to Strengthen Nephrology and Transplant Care in India

Emcure Pharmaceuticals has signed a distribution agreement with Roche for select therapies used in nephrology and transplant care in India.  

The agreement will take effect from 1 April 2026 and covers the domestic distribution of Roche’s established products in these segments.  

The development was disclosed through an exchange filing issued on March 2, 2026. 

Coverage of CKD and Post-Transplant Therapies 

The agreement includes Roche’s products used in chronic kidney disease (CKD) and transplant-related treatment. These are: 

• CellCept, an immunosuppressant used in organ transplant care since 1995. 
• Mircera, a long-acting therapy for anaemia in CKD, administered once every 2 to 4 weeks. 
• Neorecormon, also used in anaemia management for kidney disease patients.  

These medicines form part of Roche’s nephrology and transplant portfolio globally. 

Portfolio Addition for Emcure 

Emcure already has an existing presence in anaemia management and renal care. The addition of Roche’s therapies is expected to extend its offerings in chronic kidney disease and transplant-related treatment segments.  

The collaboration focuses on improving the availability of these therapies through Emcure’s domestic distribution network. 

Emcure Pharmaceuticals Background 

Emcure Pharmaceuticals, headquartered in Pune, was established in 1981 and operates across more than 70 countries. The company ranked 13th in India by domestic pharmaceutical sales for the twelve months ending October 2025.  

Roche’s India operations began in 1994 through its wholly owned subsidiary. The parent group, based in Basel, Switzerland, has been active in biotechnology and pharmaceutical innovation for over 128 years.  

Read More: IDFC First Bank Announces Merger with IDFC Ltd.! 

Emcure Pharmaceuticals Share Price Performance  

As of March 2, 2026, 3:30 pm, Emcure Pharmaceuticals share price closed at ₹1,454.20, a 0.089% decrease from the previous closing price. 

Conclusion 

The agreement allows Emcure to distribute Roche’s nephrology and transplant therapies in India from April 2026. It brings Roche’s existing treatments into Emcure’s distribution framework across the country. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.   
 
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.